A novel tool for rapidly identifying the genetic "fingerprints" of cancer cells may enable future surgeons to more accurately ...
“The BRAFTOVI regimen is emerging as a new standard of care as the first targeted therapy approved for use as early as first-line for patients with mCRC with a BRAF V600E mutation. We look ...
Braftovi, Erbitux, and mFOLFOX6 improved ORR to 60.9% in BRAF V600E-mutated mCRC compared to 40% with mFOLFOX6 alone. The FDA granted accelerated approval for the combination therapy in December 2024, ...
“Despite the high unmet need in this patient population, prior to the recent encorafenib combination regimen approval, there were no approved biomarker-driven therapies indicated for people with ...
Hosted on MSN21d
Dual-Targeted Therapies Plus Chemo Improve Objective Response Rate in BRAF V600E Metastatic CRCT UESDAY, Feb. 4, 2025 (HealthDay News) -- For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard chemotherapy (modified folinic acid ...
Braftovi is an oral small-molecule kinase inhibitor that targets BRAF V600E. The phase III BREAKWATER study is evaluating the candidate's safety and efficacy in combination with Eli Lilly’s LLY ...
This combo regimen got the FDA's accelerated approval in December 2024, marking it as the first targeted therapy available for first-line treatment in BRAF V600E-mutant mCRC patients. The results?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results